Claire Keating, MD
Pulmonary Disease · New York, NYNPI 1902069297
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $31,208 of the $32,237 with a category attached, or 96.8%. Vertex accounts for 97.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $13,685 and has fallen 65.0% since, to $4,787 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $848.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$31K
- Boehringer Ingelheim$244
- GSK$187
- Insmed, Inc.$116
- Baxter Healthcare$100
- AstraZeneca$48
- plus $188 from 7 others
Across 17 payments — averaging $70,567 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$1.2M
What the payments were for
- Consulting fees$31,20897%
- Travel & lodging$1400%
- Food & beverage$7902%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 8 | $31,354 |
| Boehringer Ingelheim | 3 | $244 |
| GSK | 9 | $187 |
| Insmed, Inc. | 2 | $116 |
| Baxter Healthcare | 4 | $100 |
| AstraZeneca | 3 | $48 |
| Gilead | 2 | $47 |
| AbbVie | 2 | $41 |
| Philips North America LLC | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $17 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRIKAFTA$2,448
How this compares
$32,237 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 60 | $1,708,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 280 | $225,903 |
| Fasenra PenBenralizumab | 32 | $179,306 |
| OfevNintedanib Esylate | 11 | $150,030 |
| Dupixent PenDupilumab | 16 | $69,054 |
| CreonLipase/Protease/Amylase | 11 | $63,475 |
| Breo ElliptaFluticasone/Vilanterol | 106 | $53,560 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $34,489 |
| Advair HfaFluticasone Propion/Salmeterol | 86 | $29,104 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $22,178 |
| Spiriva RespimatTiotropium Bromide | 33 | $21,953 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $18,526 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 457 | $14,909 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $13,392 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 48 | $8,597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $31,354 | $1,708,90760 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $187 | $315,032461 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $244 | $177,58056 claims |
| AbbVieCreon | $41 | $63,47511 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $48 | $58,004130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.